Corporate Changes - Wang Ying, the chairman of Pudong Jinqiao, has resigned due to work transfer [2] - Xu Yinghui has become the new actual controller of Gu Ao Technology after a voting rights entrustment agreement [4][5] Profit Distribution - Xiangsheng Medical plans to distribute a cash dividend of 3 yuan per 10 shares for the first three quarters of 2025 [3] Investment Projects - Jiaze New Energy intends to invest approximately 3.557 billion yuan in a green hydrogen and methanol co-production project in Jixi City, Heilongjiang Province [6] - Longfei Optical Fiber's subsidiary plans to participate in establishing an investment fund with a total subscription amount of 830 million yuan [11] Financing Activities - Jinpan Technology has received approval from the China Securities Regulatory Commission to issue convertible bonds to unspecified investors [7] Acquisitions - Zoli Pharmaceutical has signed an agreement to acquire a multi-trace element injection asset group from Future Medicine for a total price of 356 million yuan [8] Product Approvals - Nine安 Medical's U.S. subsidiary has received pre-market notifications from the FDA for its multi-detection kits for various viruses [9] National Projects - Saiyi Information has been approved to lead a national major science and technology project focused on intelligent manufacturing systems and robotics [10]

Core Viewpoint - Zhejiang Zuoli Pharmaceutical Co., Ltd. announced the acquisition of an asset group related to various trace element injection solutions for a total price of RMB 35.6 million, which includes both marketed and in-development products [1] Group 1: Acquisition Details - The asset group includes marketed products "Trace Element Injection (I)" and "Trace Element Injection (II)", as well as the in-development "Trace Element Injection (III)" along with related R&D production technical data, marketing licenses, trademarks, and patents [1] - The trace element injections are a primary source of trace elements for parenteral nutrition, particularly suitable for children and critically ill patients [1] Group 2: Market Potential - The overall market size for trace element injections is projected to reach approximately RMB 1.8 billion by 2024, with continued growth expected, especially in pediatric nutrition support and adult critical care nutrition [1] - The market is anticipated to expand further with the introduction of new products, deeper market education, and increased patient acceptance [1] Group 3: Strategic Importance - The acquisition is a significant step in completing the company's "full-age coverage" strategy, filling a gap in the pediatric treatment area and extending the product line to key scenarios in children's and elderly nutrition support [2] - The company aims to build a comprehensive health product and service chain that spans children, adults, and the elderly, aligning with national health development strategies [2] Group 4: Competitive Advantage - The company plans to leverage its existing marketing system and the advantages of the acquired asset group to drive growth, benefiting from established market foundations and procurement qualifications [3] - The trace element injections have a solid market presence, and the company's experience in clinical promotion across multiple departments will facilitate collaborative development with the new product line [3] - The asset group is expected to enhance the company's profitability and market competitiveness, with a projected net profit of RMB 45.79 million for the first nine months of 2025 [3]

Group 1 - Pudong Jinqiao's chairman Wang Ying has resigned due to job transfer, ceasing to hold positions as director, chairman, and committee member [2] - Xiangsheng Medical plans to distribute a cash dividend of 3 yuan per 10 shares to all shareholders based on the total share capital [3] - Gu Ao Technology's actual controller has changed to Xu Yinghui, with stock resuming trading on December 15 [4] Group 2 - Jiaze New Energy plans to invest approximately 3.557 billion yuan in a green hydrogen and aviation fuel chemical co-production project in Jixi City [5] - Jinpan Technology has received approval from the China Securities Regulatory Commission to issue convertible bonds to unspecified investors [6] - Zoli Pharmaceutical intends to acquire a multi-trace element injection asset group for a total price of 356 million yuan [7] Group 3 - Jiuan Medical's U.S. subsidiary has received pre-market notifications from the FDA for four and three-in-one testing products [8] - Saiyi Information has been approved for a national major science and technology project focusing on intelligent manufacturing systems and robotics [9] - Changfei Fiber's subsidiary plans to participate in establishing an investment fund with a total subscription amount of 830 million yuan [10] Group 4 - Chengfeng Technology's shareholder, Hangzhou Hongwo, plans to reduce its stake by up to 3% of the company's shares [12] - Minxin Co., Ltd.'s deputy general manager plans to reduce holdings by up to 220,000 shares, representing 0.3925% of the total share capital [13] - Xinle Energy's director plans to reduce holdings by up to 400,000 shares, accounting for 0.07% of the total share capital [14]

Core Viewpoint - Zhaoli Pharmaceutical (300181.SZ) announced the signing of an asset acquisition agreement with Tibet Future Biopharmaceutical Co., Ltd. and its subsidiaries for a total price of RMB 356 million to acquire a multi-trace element injection asset group [1] Group 1: Acquisition Details - The asset group includes already marketed products "Multi-trace Element Injection (I)" and "Multi-trace Element Injection (II)", as well as the in-development product "Multi-trace Element Injection (III)" [1] - The acquisition encompasses research and production technical data, marketing licenses, trademarks, patents, contractual rights and obligations, and employee labor relations [1]

Core Viewpoint - Zhaoli Pharmaceutical (300181) announced the acquisition of a multi-trace element injection asset group from Tibet Future Biopharmaceutical Co., Ltd. for a total price of 356 million yuan, which includes both marketed and research products [1] Group 1: Acquisition Details - The asset group includes the marketed products "Multi-trace Element Injection (I)" and "Multi-trace Element Injection (II)", as well as the research product "Multi-trace Element Injection (III)" [1] - The acquisition encompasses research and production technical data, marketing licenses, trademarks, patents, contractual rights and obligations, and employee labor relations [1] Group 2: Strategic Implications - The acquisition is expected to optimize the company's product structure and expand its treatment areas, particularly focusing on diseases affecting women, children, and the elderly [1] - This move aligns with the national health development strategy, aiming to establish a comprehensive health product and service chain that covers all age groups from children to the elderly [1]

每经AI快讯，佐力药业（SZ 300181，收盘价：18.32元）12月14日晚间发布公告称，根据公司战略布局 和经营发展需要，为了进一步优化产品结构，巩固和提升公司的综合竞争力及可持续发展能力，公司拟 购买西藏未来及其两家全资子公司许昌未来和合肥未来的"多种微量元素注射液资产组"，并签署《多种 微量元素注射液资产组收购协议书》。根据天源资产评估有限公司出具的资产评估报告，并经各方友好 协商，资产组的转让总价（含税）为人民币3.56亿元。 2025年1至6月份，佐力药业的营业收入构成为：医药制造占比78.39%，医药流通占比21.35%，其他业 务占比0.26%。 （记者 王晓波） 截至发稿，佐力药业市值为128亿元。 每经头条（nbdtoutiao）——美股AI突变！OpenAI沦为"股价毒药"，硅谷八巨头一夜蒸发3.8万亿元市 值，专家：看好谷歌，其拥有两项致胜"法宝" ...

Core Viewpoint - Zhaoli Pharmaceutical has signed an asset acquisition agreement to purchase a variety of trace element injection assets from Tibet Future Biopharmaceutical Co., Ltd. for a total price of 356 million yuan, including tax [1] Group 1: Acquisition Details - The acquisition includes the research and production technical data, marketing approvals, trademarks, patents, contractual rights and obligations, and employee labor relations related to the products [1] - The asset group consists of the already marketed products "Multiple Trace Element Injection (I)" and "Multiple Trace Element Injection (II)", as well as the in-development product "Multiple Trace Element Injection (III)" [1]

2、本次收购所涉资产组委托生产药品上市许可证（B证）办理、药品上市 许可持有人变更、集采中选省份变更等需要履行相关审批手续，且推进时间较长， 产品未来的具体销售情况可能受到市场环境变化等因素影响，均存在一定的不确 定性，敬请投资者注意投资风险。 3、本次交易不构成关联交易，亦不构成《上市公司重大资产重组管理办法》 规定的重大资产重组，无需提交公司股东会审议。 一、交易概述 证券代码：300181 证券简称：佐力药业 公告编号：2025-067 浙江佐力药业股份有限公司 关于购买资产组暨签署收购协议的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 特别提示： 1、浙江佐力药业股份有限公司（以下简称"公司"、"佐力药业"、"甲方"） 于2025年12月12日与西藏未来生物医药股份有限公司（以下简称"西藏未来"）及 其两家全资子公司许昌未来制药有限责任公司（以下简称"许昌未来"）和合肥市 未来药物开发有限公司（以下简称"合肥未来"）（以上交易对方合称"未来医药"） 签署了《多种微量元素注射液资产组收购协议书》，拟以总价（含税）人民币35,600 万元收购其多种 ...

证券代码：300181 证券简称：佐力药业 公告编号：2025-068 浙江佐力药业股份有限公司 第八届董事会第十一次（临时）会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没 有虚假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 浙江佐力药业股份有限公司（以下简称"公司"）第八届董事会第十一次（临 时）会议于 2025 年 12 月 12 日在公司会议室以现场结合通讯方式召开。会议通 知于 2025 年 12 月 7 日以专人送达、电话、传真及电子邮件等相结合方式送达各 董事。会议应出席董事 9 人，实际出席董事 9 人（其中独立董事朱建先生以通讯 表决方式审议表决）。会议由公司董事长俞有强先生主持，公司高管列席会议。 会议的召开符合《中华人民共和国公司法》《公司章程》的规定。 二、董事会会议审议情况 1、审议通过《关于购买资产组暨签署收购协议的议案》 为落实战略布局和经营发展需要，进一步优化产品结构，巩固和提升公司的 综合竞争力及可持续发展能力，同意公司购买西藏未来生物医药股份有限公司及 其两家全资子公司许昌未来制药有限责任公司和合肥市未来药物开发有限公司 的多种微量元素注射 ...

证券代码：300181 证券简称：佐力药业 公告编号：2025-069 1、案件所处的诉讼阶段：一审判决（驳回原告全部诉讼请求）。 二、本次诉讼的进展情况 2、上市公司控股子公司所处的当事人地位：被告。 3、涉案金额：111,375,804.89 元。 浙江佐力药业股份有限公司 4、对上市公司损益产生的影响：本次诉讼一审判决驳回原告全部诉讼请求， 公司控股子公司胜诉。如原告未在法定期限内上诉，本次诉讼将不会对公司本期 利润或期后利润产生负面影响。公司将持续关注案件后续进展，并及时履行信息 披露义务。 关于控股子公司涉诉的进展公告 一、本次诉讼的基本情况 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 2023 年 12 月，浙江佐力药业股份有限公司（以下简称"佐力药业"或"公司"） 控股子公司青海珠峰冬虫夏草药业有限公司（以下简称"珠峰药业"）收到浙江省 高级人民法院（以下简称"浙江高院"）发来的《民事起诉状》《浙江省高级人民 法院一审案件受理/应诉通知书》等材料，原告杭州中美华东制药有限公司（以 下简称"华东制药"）与被告青海珠峰冬虫夏草原料有限公司（以下简 ...